Erdosteine: its relevance in COPD treatment

Bibliography

• Pauwels RA, Buist AS, Calverley PM, et al. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76
   PubMedGoogle Scholar
• MacNee W. Oxidants/antioxidants and COPD. Chest 2000;117:303S-17S
   PubMed Web of Science ®Google Scholar
• Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:65-376
   Google Scholar
• Rahman I, MacNee W. Oxidant/antioxidant imbalance in smokers and in chronic obstructive pulmonary disease. Thorax 1996;51:348-50
   PubMed Web of Science ®Google Scholar
• Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997;10:1380-91
   PubMed Web of Science ®Google Scholar
• Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055-60
   PubMed Web of Science ®Google Scholar
• Finiguerra M, Conti P, Figura I, et al. Clinical study on the effects of an antibiotic and mucolytic association (amoxicillin and domiodol) in hypersecretory chronic bronchopulmonary diseases. Curr Ther Res 1982;31:895-905
   Web of Science ®Google Scholar
• Peralta J, Poderoso JJ, Corazza C, et al. Ambroxol plus amoxicillin in the treatment of xacerbations of chronic bronchitis. Arzneimittelforschung 1987;37:969-71
   PubMed Web of Science ®Google Scholar
• Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):238S-49S; review
   Web of Science ®Google Scholar
• Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD001287
   PubMedGoogle Scholar
• Busin S. Erdosteine: evaluation of mucorheological and immunosecretory parameters in patients with bronchial phlogistic pathology. Med Praxis 1991;12:197-205
   Google Scholar
• Marchioni CF, Moretti M, et al. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 1990;168:285-93
   PubMed Web of Science ®Google Scholar
• Olivieri D, Del Donno M, Casalini A, et al. Respiration 1991;58:91-4
   Google Scholar
• Scuri R, Giannetti P, Paesano A. Effect of erdosteine and its metabolites on tracheobronchial mucus production and transport. Drug Exp Clin Res 1988;14:693-8
   PubMedGoogle Scholar
• Braga PC. Dal Sasso M, Sala MT, et al. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneim-Forsch/Drug Res 1999;49:344-50
   PubMed Web of Science ®Google Scholar
• Miyake K, Kaise T, Hosoe H, et al. The effect of erdosteine on reactive oxygen species production by inflammatory cells. Inflamm Res 1999;48:205-09
   PubMed Web of Science ®Google Scholar
• Hosoe H, Kaise T, Ohmori K. Effects on the reactive oxygen species of erdosteine and its metabolite in vitro. Arzneimittel 2002;52:435-40
   PubMed Web of Science ®Google Scholar
• Braga PC, Dal Sasso M, Zuccotti T. Assessment of the antioxidant activity of the SH Metabolite 1 of erdosteine on human neutrophils respiratory burst. Arzneim Forsch Drug Res 2000;50:739-46
   PubMed Web of Science ®Google Scholar
• Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res 2007;55:249-54
   PubMed Web of Science ®Google Scholar
• Basyigit I, Yildiz F, Cekmen M, et al. Effects of erdosteine on smoking-induced lipid peroxidation in healthy smokers. Drugs R 2005;6:83-9
   PubMedGoogle Scholar
• Dal Negro RW, Visconti M, Micheletto C, et al. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther 2008;21:304-8
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Visconti M, Trevisan F, et al. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. Ther Adv Respir Dis 2008;2:271-7
   PubMedGoogle Scholar
• Dal Negro RW, Visconti M, Tognella, et al. Erdosteine affects eicosanoid production in asthma and COPD. Eur Resp J 2008;32 (Suppl 52):364s
   Google Scholar
• Ricevuti G, Mazzone A, Uccelli E, et al. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax 1988;43:585-90
   PubMed Web of Science ®Google Scholar
• Bisetti A, Mancini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivio di Medicina Interna 1995;47:89-97
   Google Scholar
• Marchioni CF, Polu JM, Taytard A, et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Intern J Clin Pharmacol Ther 1995;33:612-18
   PubMed Web of Science ®Google Scholar
• Mohanty KC, Thiappanna G, Sing V, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin Research 2001;4:35-9
   Google Scholar
• Fumagalli G. Erdosteine: a new molecule with mucolytic activity. Clinical and instrumental evaluation in patients with acute and exacerbated chronic bronchopneumopathies. Ital. J Chest Dis 1988;42:299-308
   Google Scholar
• Tellings JC. Erdosteine: original secretolytic drug with mucociliar activity: a controlled clinical study versus ambroxol. Med Praxis 1991;12:183-95
   Google Scholar
• Franco M, Mancini C. Controlled clinical study of erdosteine in chronic bronchitic patients. Archivio di Medicina Interna 1995;47:101-11
   Google Scholar
• Zanasi A, Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies. Med Praxis 1991;12:207-17
   Google Scholar
• Haughney J, Grishchenko M, Dakin HA, et al. Cost-effectiveness of erdosteine in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Thorax 2007;62 (Suppl III):A47
   Google Scholar
• Morice A, Moretti M, Ballabio M. Erdosteine in association with amoxicillin improves the outcome of acute exacerbations compared to amoxicillin alone in COPD patients. Thorax 2007;62 (Suppl III):A47
   Google Scholar
• Ghiringhelli G, Mancini C. Cross-over study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase: Controlled double-blind study vs placebo. Archivio di Medicina Interna 1995;67:113-20
   Google Scholar
• Aubier M, Berdah L. Etude multicentrique, controllèe en double aveugle, de l'efficacité et de la tolerance de vectrine (erdosteine) versus placebo dans le traitement de la bronchite chronique hypersecretante tabilisée. Rev Mal Respir 1999;16:521-8
   PubMed Web of Science ®Google Scholar
• Fioretti M, Bandera M. Prevention of exacerbations in chronic bronchitic patients with erdosteine. Med Praxis 1991;12:219-27
   Google Scholar
• Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004;30:143-52
   PubMedGoogle Scholar
• Greenberg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-73
   PubMed Web of Science ®Google Scholar
• Keistinen T, Tuuponen T, Kivela SL, Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years. Respir Med 1998;92:568-72
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S
   PubMed Web of Science ®Google Scholar
• Moretti M, Assereto R. The effect of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients. Eur Respir J 2006;28 (suppl 50):765s
   Google Scholar
• Dal Sasso M, Culici M, Guffanti EE, et al. A combination of budesonide and the SH-metabolite I of erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst. Pharmacology 2005;74:127-34
   PubMed Web of Science ®Google Scholar
• Mancini C. Erdosteine, the second generation mucolytic: international up-dating of clinical studies (adult and pediatrics). Archivio di Medicina Interna 1996;48:53-9
   Google Scholar
• Dechant KL, Noble S. Erdosteine. Drugs 1996;52(6):875-81
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176;454-59
   PubMed Web of Science ®Google Scholar